RRx-001 Completed Phase 2 Trials for Neuroendocrine Tumors / Small Cell Carcinoma / Non-Small Cell Lung Carcinoma / Epithelial Ovarian Cancer Treatment

Indications	Status	Purpose	Phase
DBCOND0029892 (Neuroendocrine Tumors) DBCOND0036950 (Small Cell Carcinoma) DBCOND0030527 (Non-Small Cell Lung Carcinoma) DBCOND0030546 (Epithelial Ovarian Cancer)	Completed	Treatment	2

clinicaltrials.gov Identifier	Title	Drugs
NCT02489903	RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)	Carboplatin (DB00958) Cisplatin (DB00515) Doxorubicin (DB00997) Etoposide (DB00773) Gemcitabine (DB00441) Irinotecan (DB00762) Paclitaxel (DB01229) Pemetrexed (DB00642) RRx-001 (DB12060) Vinorelbine (DB00361)